L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Immunosuppression is a key intervention in patients with solid organ transplant and is
usually achieved by combination therapy with systemic CsA or tacrolimus with azathioprine,
mycophenolate mofetil (MMF), or corticoids. However, the outcomes after lung transplantation
are poor when compared with those after heart, kidney, or liver transplantation, with a
survival rate of only 55% for recipients of lung transplants.
Additional application of aerosolised L-CsA should suppress T-cell activation in the lung
tissue and subsequently BOS development. The overall purpose of this phase-II/III study is to
obtain efficacy and safety data of L-CsA in the prevention of BOS.